Wafaa El‐Sadr

Active 1983–2025

Also published as
Wafaa El-Sadr
131
Papers
19,601
Citations
82
h-index
126
i10-index

Citations

Citations per year for Wafaa El‐Sadr1882: 1 citations1977: 1 citations1983: 1 citations1985: 1 citations1987: 2 citations1988: 8 citations1989: 15 citations1990: 17 citations1991: 12 citations1992: 9 citations1993: 6 citations1994: 11 citations1995: 5 citations1996: 15 citations1997: 15 citations1998: 23 citations1999: 33 citations2000: 36 citations2001: 35 citations2002: 36 citations2003: 31 citations2004: 67 citations2005: 128 citations2006: 83 citations2007: 99 citations2008: 105 citations2009: 115 citations2010: 135 citations2011: 152 citations2012: 147 citations2013: 162 citations2014: 136 citations2015: 159 citations2016: 157 citations2017: 116 citations2018: 114 citations2019: 519 citations2020: 396 citations2021: 357 citations2022: 229 citations2023: 181 citations2024: 309 citations2025: 119 citations2026: 3 citations1883–1976: no citations, so these years are not shown1978–1982: no citations, so these years are not shown1984: no citations, so this year is not shown1986: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,065 citing papers, 26.4% of this breakdownUnited Kingdom: 680 citing papers, 8.7% of this breakdownSouth Africa: 502 citing papers, 6.4% of this breakdownSwitzerland: 277 citing papers, 3.5% of this breakdownCanada: 239 citing papers, 3.1% of this breakdownAustralia: 234 citing papers, 3% of this breakdownFrance: 221 citing papers, 2.8% of this breakdownItaly: 215 citing papers, 2.8% of this breakdownChina: 197 citing papers, 2.5% of this breakdownGermany: 194 citing papers, 2.5% of this breakdownNetherlands: 184 citing papers, 2.4% of this breakdownSpain: 174 citing papers, 2.2% of this breakdown
0%26.4%Other 33.7%

Fields

  • Medicine78.5%
  • Immunology and Microbiology6.1%
  • Engineering4.7%
  • Health Professions2.5%
  • Biochemistry, Genetics and Molecular Biology2.2%
  • Social Sciences1.2%
  • Other4.8%

Topics

  • HIV/AIDS Research and Interventions12.7%
  • HIV-related health complications and treatments9.5%
  • HIV Research and Treatment6.8%
  • HIV/AIDS drug development and treatment6.7%
  • Tuberculosis Research and Epidemiology4.4%
  • Pneumocystis jirovecii pneumonia detection and treatment3.7%
  • Other56.2%

Coauthors

All papers

Open in search
  1. Achieving the 95 95 95 targets for all: A pathway to ending AIDS

    Authors: , , , , , , - PLoS ONE 2022 cited by 415

  2. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration

    Authors: , , , , , , , , , , , , , , , - The Lancet 2014 cited by 926

  3. Microfluidics-based diagnostics of infectious diseases in the developing world

    Authors: , , , , , , , , , , , , , , , , , - Nature Medicine 2011 cited by 752

  4. Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study

    Authors: , , , , , , , , , , , , , , - The Lancet HIV 2018 cited by 220

  5. Integrating HIV services and other health services: A systematic review and meta-analysis

    Authors: , , , , , , , , , , , - PLoS Medicine 2021 cited by 154

  6. Improving pathology and laboratory medicine in low-income and middle-income countries: roadmap to solutions

    Authors: , , , , , , , , , , , , , - The Lancet 2018 cited by 219

  7. Risk of Myocardial Infarction in Patients with HIV Infection Exposed to Specific Individual Antiretroviral Drugs from the 3 Major Drug Classes: The Data Collection on Adverse Events of Anti‐HIV Drugs (D:A:D) Study

    Authors: , , , , , , , , , , , , , , - The Journal of Infectious Diseases 2009 cited by 647

  8. Combination Antiretroviral Therapy and the Risk of Myocardial Infarction

    Authors: , - New England Journal of Medicine 2003 cited by 1,671

  9. Adherence to Pre-exposure Prophylaxis in Black Men Who Have Sex with Men and Transgender Women in a Community Setting in Harlem, NY

    Authors: , , , , , , , - AIDS and Behavior 2020 cited by 52

  10. Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ken Mayer, José A. Pérez‐Molina, Doreen Moraa, Denise Naniche, Denis Nash, Teymur Noori, Anton Pozniak, Reena Rajasuriar, Peter Reiss, Nesrine Rizk, Jürgen K. Rockstroh, Diana Romero, Caroline Sabin, David Serwadda, Laura Waters - Nature Communications 2021 cited by 159

  11. Trends in HIV prevalence, incidence, and progress towards the UNAIDS 95-95-95 targets in Malawi among individuals aged 15–64 years: population-based HIV impact assessments, 2015−16 and 2020−21

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Hetal Patel, Bharat Parekh, Wafaa El‐Sadr, Duncan Chege, Elizabeth Radin, David Hoos, Andrea Low, Elizabeth Gummerson - The Lancet HIV 2023 cited by 41

  12. Facing the New Covid-19 Reality

    Authors: , , - New England Journal of Medicine 2023 cited by 84

  13. Effect of Universal Testing and Treatment on HIV Incidence — HPTN 071 (PopART)

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Christophe Fraser, Kwame Shanaube, Peter Bock, Nulda Beyers, Helen Ayles, Sarah Fidler - New England Journal of Medicine 2019 cited by 351

  14. Comparison of 2 Doses of Liposomal Amphotericin B and Conventional Amphotericin B Deoxycholate for Treatment of AIDS‐Associated Acute Cryptococcal Meningitis: A Randomized, Double‐Blind Clinical Trial of Efficacy and Safety

    Authors: , , , , , , - Clinical Infectious Diseases 2010 cited by 174

  15. Achieving the fourth 90

    Authors: , , - AIDS 2018 cited by 135

  16. Scale-up of HIV Treatment Through PEPFAR

    Authors: , , , , , , , , , , , , , , - JAIDS Journal of Acquired Immune Deficiency Syndromes 2012 cited by 135

  17. Financial Incentives for Linkage to Care and Viral Suppression Among HIV-Positive Patients

    Authors: , , , , , , , , , , , , , , , , - JAMA Internal Medicine 2017 cited by 134

  18. Timing of Initiation of Antiretroviral Drugs during Tuberculosis Therapy

    Authors: , , , , , , , , , , , , , , - New England Journal of Medicine 2010 cited by 673

  19. Why reinvent the wheel? Leveraging the lessons of HIV scale-up to confront non-communicable diseases

    Authors: , - Global Public Health 2011 cited by 200

  20. Atovaquone Compared with Dapsone for the Prevention ofPneumocystis cariniiPneumonia in Patients with HIV Infection Who Cannot Tolerate Trimethoprim, Sulfonamides, or Both

    Authors: , , , , , , , , , , , - New England Journal of Medicine 1998 cited by 176

  21. Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration

    Authors: , , , , , , , , , , , , , , - BMC Medicine 2016 cited by 120

  22. Contact Tracing: Barriers and Facilitators

    Authors: , , , - American Journal of Public Health 2022 cited by 51

  23. Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study

    Authors: , , , , , , , , , , , , , , - AIDS 2003 cited by 987

  24. Incidence and Risk Factors for New-Onset Diabetes in HIV-Infected Patients

    Authors: , , , , , , , , , , , - Diabetes Care 2008 cited by 479